מכפיל P/S עתידי: Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics (VVOS) is implementing eco-friendly plastics and remote diagnostics, confirming the issuer's projected P/S ratio within the GURU.Markets chronology, where 0.20 determines the current value of the metric. Fundamentals are bolstered by high margins driven by a unique sleep apnea treatment platform, while an R&D breakthrough in non-invasive jaw correction devices promises a radical replacement for CPAP machines.

Institutional capital assesses the investment attractiveness of Vivos Therapeutics (VVOS) through the lens of the ratio between current market value and projected sales. The expected P/S metric calculates this coefficient in real-time, allowing for a comparison of the market price against the efficiency of the commercial rollout of devices under Kirk Huntsman's leadership, which confirms the asset's fundamental stability without overpaying for future growth.